ReEmerge is developing Cognitive Network Restoration Therapy (CNRT) for people with chronic cognitive impairment after brain injury. The treatment targets underactive but viable neural circuits in the central thalamus to restore function across disrupted brain networks; the company is advancing this restorative approach through clinical development.
415 Capital
415capital.com ↗Activity from announced rounds
415 Capital is a specialist venture capital firm investing in medical technology companies and supporting clinical development and commercialization.
Specialist medical technology investment
415 Capital backs medical innovation with capital, operating expertise and market access. Its portfolio spans areas such as cardiovascular devices, medical robotics, imaging and neuromodulation. The firm’s website distinguishes its 415 Capital fund families from CardioVentures.
Activity recorded on RoundOS
The RoundOS financing records include Endovascular Engineering, which develops clot-removal technology, and ReEmerge, which is developing deep-brain stimulation for cognitive deficits following traumatic brain injury. These records are examples of the firm’s medical-device activity, rather than a complete account of its investments or an allocation to a particular fund.
Sources
- Rounds participated in
- 2
- Confirmed lead rounds
- 0 1 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $117M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionDevelops thrombectomy systems for venous thromboembolism treatment